Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

about

Regulation of Bim in Health and Disease Disrupting the networks of cancer Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.

P2860

Q26781203-EA856F7F-E4A3-49FF-82AC-FB9211411611 Q28656016-DED5273A-9E13-4B59-B289-8A32396F7390 Q39168624-CABC35F1-F468-4D50-9AA4-DE1BF6E7E742

P2860

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

Item

http://www.wikidata.org/entity/Q44004521

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@en

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@nl

type

Item

label

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@en

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@nl

prefLabel

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@en

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@nl

P1476

Transcriptomic rationale for t ...... methasone in multiple myeloma.

@en

P2093

Antonio Garcia-Gomez

http://www.w3.org/2001/XMLSchema#string

Diego Fernandez-Lazaro

http://www.w3.org/2001/XMLSchema#string

Edvan de Queiroz Crusoe

http://www.w3.org/2001/XMLSchema#string

Francis Y Lee

http://www.w3.org/2001/XMLSchema#string

Jesus Martin-Sanchez

http://www.w3.org/2001/XMLSchema#string

Laura San-Segundo

http://www.w3.org/2001/XMLSchema#string

Manuel Delgado

http://www.w3.org/2001/XMLSchema#string

P2860

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Macrophage inflammatory protein-1alpha is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor kappaB ligand.

A therapeutic role for targeting c-Myc/Hif-1-dependent signaling pathways.

myc function and regulation.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.

Improved survival in multiple myeloma and the impact of novel therapies.

Targeting the phosphatidylinositol 3-kinase pathway in multiple myeloma.

New therapies in multiple myeloma.

Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.

P304

257-269

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00277-011-1287-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21720745

http://www.w3.org/2001/XMLSchema#string

P921

transcriptome

dexamethasone

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

about

P2860

P2860

Transcriptomic rationale for the synergy observed with dasatinib + bortezomib + dexamethasone in multiple myeloma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P921